GlassScriptPhysician profile
Diana Jo Remenar
NPI 1174046619
$10,804.62
in general payments reported to CMS, 2019-2025
28 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $783 · 2022: $1,684 · 2023: $3,246 · 2024: $2,765 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,338.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,372.30 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,266.68 | 2021-2025 | Rexulti, Abilify Mycite, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,181.48 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $818.97 | 2021-2022 | |
| Lundbeck LLC | $702.38 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $649.59 | 2021-2025 | Ingrezza |
| Abbvie INC. | $617.37 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $581.44 | 2022-2025 | Spravato |
| Axsome Therapeutics, INC. | $535.30 | 2022-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $440.70 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $377.16 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $331.37 | 2024-2025 | Fanapt |
| Neos Therapeutics, LP | $307.59 | 2021-2025 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $305.85 | 2022-2024 | Quviviq |
| Tris Pharma INC | $206.95 | 2022-2025 | Dyanavel Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $161.26 | 2023-2025 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $153.82 | 2023-2024 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $145.63 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $141.60 | 2024-2025 | Cobenfy |
| Corium, LLC | $134.08 | 2022-2023 | Azstarys, Adlarity |
| Merck Sharp & Dohme LLC | $123.49 | 2021-2023 | Belsomra |
| Livanova USA, INC. | $65.94 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Ironshore Pharmaceuticals INC. | $42.97 | 2022 | |
| Novo Nordisk INC | $35.23 | 2023-2024 | |
| Harmony Biosciences LLC | $30.63 | 2023 | Wakix |
| Eisai INC. | $27.72 | 2021 | |
| Adlon Therapeutics L.P. | $24.64 | 2021 | |
| Owp Pharmaceuticals, INC. | $22.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Remenar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.